Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$1.99|
|52 Week High||AU$0.99|
|52 Week Low||AU$2.53|
|1 Month Change||-5.24%|
|3 Month Change||22.09%|
|1 Year Change||82.57%|
|3 Year Change||58.57%|
|5 Year Change||111.70%|
|Change since IPO||-73.11%|
Recent News & Updates
Here's Why We're Not At All Concerned With Neuren Pharmaceuticals' (ASX:NEU) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
|NEU||AU Pharmaceuticals||AU Market|
Return vs Industry: NEU exceeded the Australian Pharmaceuticals industry which returned -2.4% over the past year.
Return vs Market: NEU exceeded the Australian Market which returned 20.2% over the past year.
Stable Share Price: NEU is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: NEU's weekly volatility (8%) has been stable over the past year.
About the Company
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has completed Phase II clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase I clinical trial for the treatment of Phelan-McDermid, Angelman, and Pitt Hopkins syndromes.
Neuren Pharmaceuticals Fundamentals Summary
|NEU fundamental statistics|
Is NEU overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|NEU income statement (TTM)|
|Cost of Revenue||AU$10.11m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.098|
|Net Profit Margin||-1,728.87%|
How did NEU perform over the long term?See historical performance and comparison
Is Neuren Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate NEU's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate NEU's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: NEU is unprofitable, so we can't compare its PE Ratio to the Oceanic Pharmaceuticals industry average.
PE vs Market: NEU is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate NEU's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: NEU is overvalued based on its PB Ratio (15.1x) compared to the AU Pharmaceuticals industry average (3.3x).
How is Neuren Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Neuren Pharmaceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Neuren Pharmaceuticals performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: NEU is currently unprofitable.
Growing Profit Margin: NEU is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: NEU is unprofitable, and losses have increased over the past 5 years at a rate of 2.3% per year.
Accelerating Growth: Unable to compare NEU's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NEU is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (17.1%).
Return on Equity
High ROE: NEU has a negative Return on Equity (-74.49%), as it is currently unprofitable.
How is Neuren Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: NEU's short term assets (A$19.0M) exceed its short term liabilities (A$2.4M).
Long Term Liabilities: NEU has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: NEU is debt free.
Reducing Debt: NEU has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: NEU has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: NEU has sufficient cash runway for 2 years if free cash flow continues to grow at historical rates of 12.1% each year.
What is Neuren Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate NEU's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate NEU's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if NEU's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if NEU's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of NEU's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mr. Jonathan Charles Pilcher, also known as Jon, BSc (Hons), ACA serves as Managing Director at Neuren Pharmaceuticals Limited since June 14, 2021. He had been a Company Secretary at Neuren Pharmaceuticals...
Experienced Management: NEU's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.
Experienced Board: NEU's board of directors are considered experienced (3.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 9.9%.
Neuren Pharmaceuticals Limited's employee growth, exchange listings and data sources
- Name: Neuren Pharmaceuticals Limited
- Ticker: NEU
- Exchange: ASX
- Founded: 2001
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: AU$250.672m
- Shares outstanding: 125.97m
- Website: https://www.neurenpharma.com
Number of Employees
- Neuren Pharmaceuticals Limited
- 697 Burke Road
- Suite 201
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/16 07:04|
|End of Day Share Price||2021/10/15 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.